Expression of vascular endothelial growth factor (VEGF) and its receptors in human neuroblastoma

European Journal of Cancer

Volumn 35, Issue 3, 1999, Pages 445-449

  Meister, B ^a   Grunebach F ^a   Bautz, F ^a   Brugger, W ^a   Fink, F M ^b   Kanz, L ^a   Mohle R ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY OF INNSBRUCK   (Austria)

Author keywords

Anglogenesis; FLK 1; FLT 1; Neuroblastoma; VEGF

Indexed keywords

ANGIOGENIC FACTOR; GROWTH FACTOR; NEUTRALIZING ANTIBODY; PROTEIN TYROSINE KINASE; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ADOLESCENT; ARTICLE; CANCER GROWTH; CANCER INVASION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MALIGNANT TRANSFORMATION; NEOVASCULARIZATION (PATHOLOGY); NEUROBLASTOMA; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TISSUE HOMOGENATE; VASCULAR TUMOR;

ADOLESCENT; CHILD, PRESCHOOL; ENDOTHELIAL GROWTH FACTORS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INFANT; LYMPHOKINES; MALE; NEOVASCULARIZATION, PATHOLOGIC; NEUROBLASTOMA; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0033105792     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(98)00387-6     Document Type: Article

References (28)

1. Brodeur G.M., Pritchard J., Berthold F., et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol. 11:1993;1466-1477.
2. Brodeur GM, Castleberry RP. Neuroblastoma. In Pizzo PA, Poplac DG, eds. Principles and Practice of Pedriatic Oncology, 3rd edn. Philadelphia, Lippincott-Raven, 1997, 761-797.
3. Quinn J.J., Altmann A.J. The multiple hematologic manifestation of neuroblastoma. Am J Pediatr Hematol Oncol. 1:1979;201-205.
4. Gaudin P.B., Rosai J. Florid vascular proliferation associated with neural and neuroendocrine neoplasms. A diagnostic clue and potential pitfall. J Am Surg Pathol. 19:1995;642-652.
5. Folkman J. The role of angiogenesis in tumor growth. Semin Cancer Biol. 3:1992;65-71.
6. Senger D.R., VandeWater L., Brown L.F., et al. Vascular permeability factor (VPF, VEGF) in tumor biology. Cancer Metastasis Rev. 12:1993;303-324.
7. Möhle R., Green D., Moore M.A.S., Nachman R.L., Rafii S. Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets. Proc Natl Acad Sci USA. 94:1997;663-668.
8. Senger D.R., Connolly D.T., VanDeWater L., Feder J., Dvorak H.F. Purification and NH2-terminal amino acid sequence of guinea pig tumor secreted vascular permeability factor. Cancer Res. 50:1990;1774-1778.
9. Houck K.A., Ferrara N., Winer J., Cachianes G., Li B., Leung D.W. The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol Endocrinol. 5:1991;1806-1814.
10. Terman B.I., Dougher-Vermazen M., Carrion M.E., et al. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem Biophys Res Commun. 187:1992;1579-1586.
11. DeVries C., Escobedo J.A., Ueno H., Houck K., Ferrara N., Williams L.T. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science. 255:1992;989-991.
12. Seetharam L., Gotoh N., Maru Y., Neufeld G., Yamaguchi S., Shibuya M. A unique signal transduction from FLT tyrosine kinase, a receptor for vascular endothelial growth factor VEGF. Oncogene. 10:1995;135-147.
13. Barleon B., Sozzani S., Zhou D., Weich H.A., Mantovani A., Marme D. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor fit-1. Blood. 87:1996;3336-3343.
14. Plate K.H., Breier G., Weich H.A., Risau W. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature. 359:1992;845-848.
15. Brown LF, Berse B, Jackman RW, et al. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract. Cancer Res 1993, 53, 4727-4735.
16. Boocock C.A., Charnock-Jones D.S., Sharkey A.M., et al. Expression of vascular endothelial growth factor and its receptors fit and KDR in ovarian carcinoma. J Natl Cancer Inst. 87:1995;506-516.
17. Brown L.F., Berse B., Jackman R.W., et al. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. Hum Pathol. 26:1995;86-91.
18. Yoshiji H., Gomez D.E., Shibuya M., Thorgeirsson U.P. Expression of vascular endothelial growth factors, its receptors, and other angiogenic factors in human breast cancer. Cancer Res. 56:1996;2013-2016.
19. Jackson M.W., Bentel J.M., Tilley W.D. Vascular endothelial growth factor (VEGF) expression in prostate cancer and benign prostatic hyperplasia. J Urol. 157:1997;2323-2328.
20. Schlaeppi J.M., Eppenberger U., Martiny-Baron G., Kung W. Chemiluminescence immunoassay for vascular endothelial growth factor (vascular permeability factor) in tumor tissue homogenates. Clin Chem. 42:1996;1777-1784.
21. Levy A.P., Tamargo R., Brem H., Nathans D. An endothelial cell growth factor from the mouse neuroblastoma cell line NB41. Growth Factors. 2:1989;9-19.
22. Ribatti D., Alessandri G., Vacca A., Iurlaro M., Ponzoni M. Human neuroblastoma cells produce extracellular matrix-degrading enzymes, induce endothelial cell proliferation and are angiogenic in vivo. Int J Cancer. 77:1998;449-454.
23. Meitar D., Crawford S.E., Rademaker A.W., Cohn S.L. Tumor angiogenesis correlate with metastatic disease, N-myc amplification, and poor outcome in human neuroblastoma. J Clin Oncol. 14:1996;405-414.
24. Kim K.J., Li B., Winer J., et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature. 362:1993;841-844.
25. Jeffers M., Schmidt L., Nakaigawa N., et al. Activating mutations for the met tyrosine kinase receptor in human cancer. Proc Natl Acad Sci USA. 94:1997;11445-11450.
26. Huang H.S., Nagane M., Klingbeil C.K., et al. The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling. J Biol Chem. 272:1997;2927-2935.
27. Soker S., Takashima S., Miao H.Q., Neufeld G., Klagsbrun M. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell. 92:1998;735-745.
28. Kitsukawa T., Shimono A., Kawakami A., Kondoh H., Fujisawa H. Overexpression of a membrane protein, neuropilin, in chimeric mice causes anomalies in the cardiovascular system, nervous system and limbs. Development. 121:1995;4309-4318.